Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,979.00
Bid: 1,988.00
Ask: 1,990.00
Change: 8.00 (0.41%)
Spread: 2.00 (0.101%)
Open: 1,973.00
High: 1,996.00
Low: 1,955.00
Prev. Close: 1,971.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks Set To Open Lower Ahead Of US Non-Farm Payrolls

Fri, 08th Nov 2013 07:48

LONDON (Alliance News) - UK equities are called to follow Asian and US stock indices lower Friday as investors await much-anticipated US jobs market data.

Stocks worldwide were dragged lower Thursday after a report from the US Commerce Department showed stronger-than-expected US third-quarter GDP growth. The report revealed that US gross domestic product rose by 2.8% in the third-quarter, from a 2.5% increase in the second-quarter, coming in ahead of economist estimates of an increase of 2.0%.

The strong figure, by dismissing signs that the US economy had slowed down through the end of the third-quarter, was seen by many as increasing the likelihood that the Federal Reserve may taper its USD85 billion-per-month asset buying programme in December.

Investor focus Friday shifts towards the health of the US jobs markets. A stronger-than-expected nonfarm payrolls report for October is likely to further increase the chance that the Fed will curb its asset-buying scheme. The data, scheduled at 1330 GMT, is expected to come in at 125,000, from 148,000 in September.

Separate US reports on personal income and spending and consumer spending, also are expected at 1330 GMT, will also provide a clearer picture on whether the US economy is resilient enough to withstand an early start to stimulus tapering.

Positive Chinese data released overnight has largely been dismissed.

China's trade surplus more than doubled in October, boosted by a stronger-than-expected rebound in exports, data from the General Administration of Customs showed Friday, suggesting that the economic recovery is gaining traction. The trade surplus jumped to USD31.1 billion in October from USD15.21 billion in September. Economists expected an increase to USD23.9 billion.

The country's exports grew 5.6% year-on-year in October compared with forecast for a 3.2% rise. For September, overseas shipments had fallen 0.3%. Imports grew 7.6% annually, faster than the 7.4% increase in the previous month, however slightly missing expectations of a rise to 8.5%.

The positive data will encourage Chinese leaders, gathering in Beijing this weekend for a key Communist Party meeting, to accelerate efforts to unlock another wave of economic reforms.

Ahead of the London open, the Nikkei trades down 1%, with the Hang Seng down 0.7%.

In the US, Wall Street closed lower Thursday. The DJIA closed down 1%, the S&P closed down 1.3%, and the Nasdaq Composite closed down 1.9%.

IG is calling the FTSE 100 to open lower at approximately 6666.0 points.

The euro is set for another volatile day Friday, having been hit Thursday on the back of the European Central Bank's rate cut and strong US third-quarter GDP growth.

Standard and Poor's has slashed France's sovereign credit ratings by one notch to 'AA', citing weak economic prospects and fiscal policy constraints.

In the wake of the decision, EURUSD and EURJPY were knocked, said CitiFX Wire's Nishtha Asthana. "The overall reaction however, is still muted," Asthana added.

However, the euro has been boosted in the aftermath of a strong German trade report. Germany's total trade surplus rose to EUR20.4 billion in September, compared to expectations for an increase of EUR15.5 billion.

Ahead of the UK equity market open, the euro trades at USD1.3410, GBP1.6101 and JPY131.632.

In Friday's data calendar, UK goods and total trade balance numbers are scheduled for 0930 GMT.

There has been a number of corporate releases ahead of the London open Friday. Blue-chip Rolls-Royce has been joined by FTSE 250-listed Hikma Pharmaceuticals, Bovis Homes and Tullett Prebon, amongst others, in releasing interim management statements. Rentokil initial has provided a trading statement. Merlin Entertainment has announced its IPO price.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
24 Feb 2022 10:31

TOP NEWS: Hikma Pharmaceutical records revenue growth and lifts payout

(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout.

Read more
24 Feb 2022 07:58

Hikma Pharmaceutical delivers year of 'solid growth' and 'strategic momentum'

(Sharecast News) - Drugmaker Hikma Pharmaceutical said on Thursday that it had delivered another successful year of "solid growth and continued strategic momentum", with both revenue and operating profits improving year-on-year.

Read more
24 Feb 2022 07:50

LONDON MARKET PRE-OPEN: Share buybacks for Lloyds Banking and Hikma

(Alliance News) - Stock prices in London are seen opening sharply lower, with the FTSE 100 called down almost 200 points, amid fear of a full-scale war in eastern Europe after Russia announced the beginning of a military operation in Ukraine.

Read more
17 Feb 2022 16:08

UK earnings, trading statements calendar - next 7 days

Friday 18 February  
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 21 February 
Bank of Cyprus Holdings PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Tristel PLCTrading Statement
Wilmington PLCHalf Year Results
Tuesday 22 February 
Antofagasta PLCFull Year Results
Bank of Georgia Group PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Blancco Technology Group PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Coca-Cola HBC AGFull Year Results
Hargreaves Lansdown PLCHalf Year Results
HSBC Holdings PLCFull Year Results (at 0400 GMT)
InterContinental Hotels Group PLCFull Year Results
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Synectics PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wednesday 23 February 
Aston Martin Lagonda Global Holdings PLCFull Year Results
Barclays PLCFull Year Results
Capital & Counties Properties PLCFull Year Results
CAP-XX LtdHalf Year Results
Georgia Capital PLCFull Year Results
International Personal Finance PLCFull Year Results
Irish Residential Properties REIT PLCFull Year Results
Metro Bank PLCFull Year Results
Hochschild Mining PLCFull Year Results
Photo-Me International PLCFull Year Results
Rio Tinto PLCFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Ted Baker PLCTrading Statement
Unite Group PLCFull Year Results
Thursday 24 February 
Anglo American PLCFull Year Results
BAE Systems PLCFull Year Results
Centrica PLCFull Year Results
Conduit Holdings LtdFull Year Results
Derwent London PLCFull Year Results
Drax Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Inchcape PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Rathbone Group PLCFull Year Results
Ricardo PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
St James's Place PLCFull Year Results
Tremor International LtdFull Year Results
WPP PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
9 Feb 2022 09:48

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Read more
3 Feb 2022 09:12

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets

Read more
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.